Aarti Pharmalabs · NSE: AARTIPHARM · BSE: 543748
Q1 FY24 results · Apr–Jun 2023
Aarti Pharmalabs reported revenue from operations of ₹458.36 crore and net profit of ₹47.09 crore for Q1 FY24 (Apr–Jun 2023), on a consolidated basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 458.36 | — | — | 485.06 | −5.5% |
| Other income | 0.48 | — | — | 0.74 | −35.1% |
| Total income | 458.84 | — | — | 485.80 | −5.5% |
| Profit before tax | 63.98 | — | — | 58.84 | +8.7% |
| Net profit for the period | 47.09 | — | — | 42.87 | +9.8% |
| Attributable to shareholders of the company | 50.97 | — | — | 42.87 | +18.9% |
| EPS, basic (₹) | 5.20 | — | — | 4.73 | +9.9% |
| Net margin (%) | 10.3 | — | 8.8 |
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 358.14 | — | — | 374.27 | −4.3% |
| Other income | 4.86 | — | — | 0.00 | — |
| Total income | 363.00 | — | — | 374.27 | −3.0% |
| Profit before tax | 62.13 | — | — | 56.74 | +9.5% |
| Net profit for the period | 47.63 | — | — | 39.99 | +19.1% |
| EPS, basic (₹) | 5.26 | — | — | 4.41 | +19.3% |
| Net margin (%) | 13.3 | — | 10.7 |
Consolidated
- Filed with BSE
- 05 Aug 2023, 17:19 IST
- Board meeting
- 05 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Aug 2023, 17:19 IST
- Board meeting
- 05 Aug 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Audited
- Source
- XBRL filing on BSE